Nivolumab + Ipilimumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Microsatellite Stable Colorectal Cancer
Conditions
Metastatic Microsatellite Stable Colorectal Cancer
Trial Timeline
Oct 5, 2020 → Jun 1, 2024
NCT ID
NCT04575922About Nivolumab + Ipilimumab
Nivolumab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Metastatic Microsatellite Stable Colorectal Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04575922. Target conditions include Metastatic Microsatellite Stable Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02186249 | Pre-clinical | Completed |
| NCT07024862 | Pre-clinical | Active |
| NCT06487156 | Pre-clinical | Active |
| NCT05219435 | Phase 2 | Active |
| NCT05302921 | Phase 2 | Completed |
| NCT05088889 | Phase 1 | UNKNOWN |
| NCT04966676 | Phase 2 | Terminated |
| NCT05215470 | Phase 2 | Active |
| NCT04465643 | Phase 1 | Completed |
| NCT04938232 | Phase 2 | Active |
| NCT04495010 | Phase 2 | Withdrawn |
| NCT04513522 | Approved | Completed |
| NCT04434560 | Phase 2 | Terminated |
| NCT04575922 | Phase 2 | UNKNOWN |
| NCT04340193 | Phase 3 | Completed |
| NCT04088500 | Phase 2 | Terminated |
| NCT04361162 | Phase 2 | Active |
| NCT03873402 | Phase 3 | Active |
| NCT03461952 | Phase 2 | Terminated |
| NCT03789110 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Microsatellite Stable Colorectal Cancer